A few points that I found of interest in Joint’s presentation....

A few points that I found of interest in Joint’s presentation. There was some emphasis on further expansion of uses for the algorithmic product.

Used for cough counting the device claims high accuracy at 99.6% precision and 91.5% recall. It has potential for use as a companion app to monitor medical treatments, providing diagnostic and biomarker feedback to inform dose size/usage etc on a continuing basis.

Joint: We are looking for partners to integrate ResApp-Dx into their platforms to enable remote diagnosis and management of chronic respiratory diseases such as asthma and COPD to reduce the burden on healthcare facilities and also with healthcare providers to streamline respiratory disease triage in clinical settings.

We are expanding our range of diagnostic algorithms to COVID-19 and tuberculosis, and also looking for partnerships in heart failure and other chronic diseases that involve coughs.


Joint’s answers to the few questions asked also were informative.

Q: “Any plans to expand applications to include smart speakers like Alexa, Google Home or Siri to capture coughs and feed your machine?”

Joint: “We have just formed a partnership with German company CarePath who have a hospital-at-home monitoring technology. So they use an internet-of-things tech with home hubs that enable the passive capture of an individual’s signature cough sound, and we’re going to collaborate with them to see if we can run our algorithms in the background on passive cough selection

And ultimately capturing their longitudinal data should enable us to train predictive algorithms so that we can actually predict an asthma or COPD exacerbation as opposed to identifying it in a quick and efficient manner in management.

In addition a focus on a device agnostic algorithm will enable us to move away from a smartphone to any device, be it a smart watch or an Amazon home or Google Alexa or a device of that type.”


Also, as part of a response to another question on current ResAppDx users:

Joint: “...The clinician feedback has been very key. They’re amazed at what the technology can do, what it does to the level of sensitivity that it does.
It has huge implications on the efficiency and timing. Being able to identify pneumonia at the point of care is key because a 4-hour delay or a 24-hour delay can have significant impacts on the quality of life for that patient.
And also in terms of patient safety the key feedback has been the patients feeling confident that they now don’t need to see a patient physically for a physical assessment for their respiratory symptoms.”

Some useful information in there.